5 Results for "

radiotherapeutic

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "radiotherapeutic" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-128890
CAS No.: 170908-81-3
Purity:  ≥95.0%
Research Areas:  

Cancer

DOTA-NHS-ester is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-128890B
Purity:  95.00%
Research Areas:  

Cancer

DOTA-NHS-ester TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
loading...
    loading...
Cat. No.: HY-128890A
CAS No.: 1823122-52-6
Research Areas:  

Cancer

DOTA-NHS-ester hexafluorophosphate TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester hexafluorophosphate TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester hexafluorophosphate TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
loading...
    loading...
Cat. No.: HY-171331
CAS No.: 2416165-76-7
Target:  

PD-1/PD-L1 Integrin

Research Areas:  

Cancer

AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells .
loading...
    loading...
Cat. No.: HY-182499
CAS No.: 1574367-80-8
Target:  

PARP

Research Areas:  

Cancer

PARP1-IN-56 (Compound RCY) is an I-labeled poly(ADP−ribose) polymerase (PARP1) inhibitor. PARP1-IN-56 can be radiolabeled with 211At or 125I for use as an α-emitting radiotherapeutic agent. PARP1-IN-56 can be used for the research of cancer .
loading...
    loading...